Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Eptinezumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting
    Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting

    17 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230417005030/en

    BUSINESSWIRE
    17 Apr 2023
    Share Share
    Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.
    Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.

    21 Oct 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119

    FDA
    21 Oct 2022
    Share Share
    Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag
    Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag

    19 Aug 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/setback-lundbeck-cgrp-migraine-drug-vyepti-hits-expansion-snag-sales-still-doubled

    Angus Liu FIERCEPHARMA
    19 Aug 2022
    Share Share
    Lundbeck to Present Data on VYEPTI at the Annual Meeting of AHS for Migraine
    Lundbeck to Present Data on VYEPTI at the Annual Meeting of AHS for Migraine

    09 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220609005304/en

    BUSINESSWIRE
    09 Jun 2022
    Share Share
    Lundbeck's Vyepti (Eptinezumab) Receives Approval in Europe
    Lundbeck's Vyepti (Eptinezumab) Receives Approval in Europe

    15 Feb 2022

    // EMA

    https://www.ema.europa.eu/en/medicines/human/EPAR/vyepti

    EMA
    15 Feb 2022
    Share Share
    Lundbeck's Biological Eptinezumab-Jjmr Receives Supplemental Approval In US
    Lundbeck's Biological Eptinezumab-Jjmr Receives Supplemental Approval In US

    24 Sep 2021

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119

    FDA
    24 Sep 2021
    Share Share